CMP Signs MOU with Singapore’s Esco Aster — Advancing Automated, GMP-Ready Cell Manufacturing

日期2025-12-12

Creative Life Science (7837.TWO) Signs MOU with Singapore’s Esco Aster (Photo by Linna Li)

A-
A+

加入收藏

Creative Life Science (CMP, sotck code 7837.TWO) has signed a strategic MOU with Esco Aster, a global life science group from Singapore, to jointly accelerate next-generation manufacturing solutions in regenerative medicine.

Creative Life Science Signs MOU with Singapore’s Esco Aster (Photo by Linna Li)

What the Partnership Brings

Co-building an integrated, automated cell manufacturing demo platform
Collaboration across Taiwan and Southeast Asia for commercialization and market expansion
Creative Life Science to support Esco’s platform adoption with GMP-grade cell culture media production

Esco Aster’s Strengths

A leading player in cell therapy, closed-system automation, and scalable CGT manufacturing
Developer of the cGMP TideMotion® bioreactor & isolation technologies
Deepening ties with Taiwan through acquisitions, IP licensing, and joint development with PITDC and multiple biotech partners

Dr. Yueh-Ting Tsai, Chairman of CMP (Photo by Linna Li)

Creative Life Science’s Vision

Chairman Dr. Yueh-Ting Tsai emphasized the shared ambition between both companies: expanding global reach, integrating software + hardware solutions, and supporting customers through end-to-end innovation.

The company is also building Taiwan’s first PIC/S GMP + ISO 13485-compliant cell culture media facility, set to open in March 2026 — strengthening upstream capabilities for Taiwan’s regenerative medicine and cell therapy ecosystem.

Stay tuned for more updates on Taiwan’s growing role in global CGT manufacturing.

(Original content was reported by Globalbio's reporter Pei-An Wu)